Related Experiment Video
Updated: Apr 26, 2026
08:25
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
Published on: June 5, 2020
6.7K
Incorporating potency into EU classification for carcinogenicity and reproductive toxicity
C Hennes1, M Batke2, W Bomann3
1ECETOC AISBL, Avenue E. van Nieuwenhuyse 2 Bte 8, Brussels B-1160, Belgium.
Regulatory Toxicology and Pharmacology : RTP
|August 6, 2014
Summary
Hazard classification in the EU needs to include chemical potency for better hazard communication. Incorporating potency, especially for carcinogenicity and reproductive toxicity, improves risk management guidance.
Area of Science:
- Chemical safety assessment
- Toxicology
- Regulatory science
Background:
- Risk assessment is often not feasible, making chemical hazard classification crucial for guidance.
- Current EU hazard classification identifies hazards but often lacks discrimination across potency levels.
Purpose of the Study:
- To advocate for the inclusion of chemical potency in EU hazard classification.
- To enhance hazard communication and downstream risk management through improved classification.
Main Methods:
- Reviewing the components of risk assessment and the purpose of chemical classification.
- Analyzing the EU's hazard classification process, particularly for carcinogenicity and reproductive toxicity.
- Proposing the incorporation of potency data into classification criteria.
Main Results:
- The EU classification system for carcinogenicity and reproductive toxicity does not adequately account for wide variations in potency.
- Potency is a critical indicator of hazard degree and should be integrated into classification.
Conclusions:
- Including chemical potency in hazard classification will provide more accurate guidance on the degree of hazard.
- This improved classification can significantly enhance hazard communication and inform risk management strategies.
Keywords:
CarcinogenicityClassificationDegree of hazardDevelopmental toxicityHazard communicationPotencyReproductive toxicityMore Related Videos
11:38High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
12.4K
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
13.4K
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
01:23Toxicity Testing in Animals
200
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
200
01:07Teratogenicity
4.2K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
01:25Bioactivation and Tissue Toxicity
151
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
151
01:22Dose-Response Relationship: Potency and Efficacy
6.8K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.8K
01:25Drug Regulation
3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K